In the evolving landscape of diabetes management, novel therapies like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist group, offer https://siobhanyhks392554.blogdeazar.com/profile